Datopotamab Deruxtecan for Triple Negative Breast Cancer

(PREDICT-RD Trial)

This trial tests a new treatment, Datopotamab Deruxtecan (an experimental drug), for individuals with triple negative breast cancer, a type that lacks three common receptors. The study aims to determine the treatment's effectiveness for patients with residual cancer after chemotherapy and surgery. It will monitor cancer recurrence using a blood test that detects tiny amounts of cancer DNA. Suitable candidates have stage II or III triple negative breast cancer with remaining cancer after initial treatment and surgery. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

A previous study found Datopotamab deruxtecan (Dato-DXd) to be generally safe. Most participants experienced mild side effects, while serious side effects were less common. Research shows that although many participants had some side effects, only a few experienced severe ones. This suggests the treatment was generally well-tolerated. The safety profile is considered manageable, offering reassurance to those considering joining a trial with this treatment.¹²³⁴⁵

Datopotamab deruxtecan is unique because it targets triple negative breast cancer (TNBC) in a novel way. Unlike standard treatments, which may include chemotherapy, this drug is an antibody-drug conjugate. It combines an antibody that specifically seeks out cancer cells with a powerful chemotherapy agent, delivering the treatment directly to the cancer cells and sparing more healthy cells. Researchers are excited about its potential to reduce recurrence risk in patients with high residual cancer burden after initial treatments.

Studies have shown that datopotamab deruxtecan (Dato-DXd) can significantly benefit patients with triple-negative breast cancer (TNBC). Specifically, research found that Dato-DXd improved overall survival by five months compared to standard chemotherapy in patients with advanced TNBC. It also reduced the risk of disease progression by 43% for those unable to receive immunotherapy. These findings suggest that Dato-DXd could be a promising option for improving outcomes in TNBC patients, particularly those with limited treatment options. The treatment has demonstrated a manageable safety profile, making it a viable choice for many patients. Participants in this trial will receive Dato-DXd, focusing on those with higher residual cancer burden post-neoadjuvant therapy.¹³⁵⁶⁷